TriSalus Life Sciences (TLSI) shares were up 5.9% in Wednesday trading after the company said late Tuesday it received US Food and Drug Administration clearance for TriNav Advance, the newest addition to its Pressure-Enabled Drug Delivery portfolio.

TriNav Advance provides access to small, distal vessels via a compatible delivery microcatheter, the company said.

The company said it plans to initiate a limited market release of the TriNav Advance device over the coming weeks.

Price: 5.22, Change: +0.29, Percent Change: +5.88

http://www.mtnewswires.com
Copyright © 2026 MT Newswires. All rights reserved. MT Newswires does not provide investment advice. Unauthorized reproduction is strictly prohibited.